InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services
Portfolio Pulse from Benzinga Newsdesk
InflaRx's GOHIBIC (Vilobelimab) has been selected by BARDA for a Phase 2 study on Acute Respiratory Distress Syndrome. The DSMB has recommended continuation without modification for the third time, with a safety review including 395 patients. An interim survival analysis is expected early 2025, and rapid enrollment positions the company for completion by Q1 2025.
June 24, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
InflaRx's GOHIBIC (Vilobelimab) has been selected by BARDA for a Phase 2 study on Acute Respiratory Distress Syndrome. The DSMB has recommended continuation without modification for the third time, with a safety review including 395 patients. An interim survival analysis is expected early 2025, and rapid enrollment positions the company for completion by Q1 2025.
The selection of GOHIBIC by BARDA for a Phase 2 study and the DSMB's recommendation to continue without modification are positive indicators for InflaRx. The rapid enrollment and expected interim survival analysis in early 2025 suggest potential for prolonged survival, which could boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100